Investigation of the Impact of Medications Used in COVID-19 Treatment and COVID-19Vaccine on Hearing
This study aims to investigate the impact of medications containing the active
ingredients hydroxychloroquine and favipiravir on the auditory system, as well as to
examine the effect of COVID-19 on hearing and its potential relationship with medication
use and COVID-19 vaccine dose.
Diagnostic Test: Hearing tests
Participants' pure tone thresholds, high frequency thresholds, and otoacoustic emissions
measurements were evaluated.
Inclusion Criteria:
Age between 18 and 35 For the Medication group: Having had COVID-19 and using COVID-19
medications For the Non-Medication group: Having had COVID-19 and not using COVID-19
medications For the Control group: Having never had COVID-19
Exclusion Criteria:
Previously diagnosed with hearing loss Use of ototoxic medications other than those
specified Pathology detected during tympanometric evaluation or otoscopic examination
Chronic disease Family history of hearing loss History of meningitis Neurological
disorders Acute or chronic ear infection Admission to intensive care
Biruni University
Istanbul, Turkey (Türkiye)
Not Provided